These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 18595435)
1. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. Erman MK; Zammit G; Rubens R; Schaefer K; Wessel T; Amato D; Caron J; Walsh JK J Clin Sleep Med; 2008 Jun; 4(3):229-34. PubMed ID: 18595435 [TBL] [Abstract][Full Text] [Related]
2. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia. Uchimura N; Kamijo A; Kuwahara H; Uchiyama M; Shimizu T; Chiba S; Inoue Y Sleep Med; 2012 Dec; 13(10):1247-53. PubMed ID: 23063301 [TBL] [Abstract][Full Text] [Related]
3. A polysomnography study of eszopiclone in elderly patients with insomnia. McCall WV; Erman M; Krystal AD; Rosenberg R; Scharf M; Zammit GK; Wessel T Curr Med Res Opin; 2006 Sep; 22(9):1633-42. PubMed ID: 16968566 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. Huedo-Medina TB; Kirsch I; Middlemass J; Klonizakis M; Siriwardena AN BMJ; 2012 Dec; 345():e8343. PubMed ID: 23248080 [TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T; Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081 [TBL] [Abstract][Full Text] [Related]
6. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Roth T; Soubrane C; Titeux L; Walsh JK; Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744 [TBL] [Abstract][Full Text] [Related]
8. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Krystal AD; Walsh JK; Laska E; Caron J; Amato DA; Wessel TC; Roth T Sleep; 2003 Nov; 26(7):793-9. PubMed ID: 14655910 [TBL] [Abstract][Full Text] [Related]
9. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Scharf M; Erman M; Rosenberg R; Seiden D; McCall WV; Amato D; Wessel TC Sleep; 2005 Jun; 28(6):720-7. PubMed ID: 16477959 [TBL] [Abstract][Full Text] [Related]
10. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Pollack M; Kinrys G; Krystal A; McCall WV; Roth T; Schaefer K; Rubens R; Roach J; Huang H; Krishnan R Arch Gen Psychiatry; 2008 May; 65(5):551-62. PubMed ID: 18458207 [TBL] [Abstract][Full Text] [Related]
11. Eszopiclone versus zopiclone in the treatment of insomnia. Pinto LR; Bittencourt LR; Treptow EC; Braga LR; Tufik S Clinics (Sao Paulo); 2016 Jan; 71(1):5-9. PubMed ID: 26872077 [TBL] [Abstract][Full Text] [Related]
12. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Boyle J; Trick L; Johnsen S; Roach J; Rubens R Hum Psychopharmacol; 2008 Jul; 23(5):385-97. PubMed ID: 18350566 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796 [TBL] [Abstract][Full Text] [Related]
14. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. Sangal RB; Blumer JL; Lankford DA; Grinnell TA; Huang H Pediatrics; 2014 Oct; 134(4):e1095-103. PubMed ID: 25266438 [TBL] [Abstract][Full Text] [Related]
15. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Najib J Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462 [TBL] [Abstract][Full Text] [Related]
16. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Roth T; Hull SG; Lankford DA; Rosenberg R; Scharf MB; Sleep; 2008 Sep; 31(9):1277-84. PubMed ID: 18788653 [TBL] [Abstract][Full Text] [Related]
17. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Menza M; Dobkin RD; Marin H; Gara M; Bienfait K; Dicke A; Comella CL; Cantor C; Hyer L Mov Disord; 2010 Aug; 25(11):1708-14. PubMed ID: 20589875 [TBL] [Abstract][Full Text] [Related]
18. Gender Differences in the Efficacy and Safety of Chronic Nightly Zolpidem. Roehrs TA; Roth T J Clin Sleep Med; 2016 Mar; 12(3):319-25. PubMed ID: 26446253 [TBL] [Abstract][Full Text] [Related]
19. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Kryger MH; Steljes D; Pouliot Z; Neufeld H; Odynski T Sleep; 1991 Oct; 14(5):399-407. PubMed ID: 1759092 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. Krystal A; Fava M; Rubens R; Wessel T; Caron J; Wilson P; Roth T; McCall WV J Clin Sleep Med; 2007 Feb; 3(1):48-55. PubMed ID: 17557453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]